When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

3. AstraZeneca to cap US out-of-pocket costs for inhalers at $35 ...

   www.aol.com/news/astrazeneca-cap-us-pocket-costs...

   Boehringer had also said it would cap out-of-pocket costs for its inhaler products for chronic lung disease and asthma to $35 per month, starting June 1. AstraZeneca to cap US out-of-pocket costs ...

4. Some drugmakers to cap cost of asthma inhalers at $35 a month

   www.aol.com/news/drugmakers-cap-cost-asthma...

   Starting Saturday, the cost of inhalers will fall for many Americans, as new out-of-pocket price caps go into effect for the asthma medications from AstraZeneca and Boehringer Ingelheim.

5. Long-acting beta-adrenoceptor agonist - Wikipedia

   en.wikipedia.org/wiki/Long-acting_beta...

   This second medication in this combination is the synthetic inhaled corticosteroid fluticasone furoate. This product was approved by the FDA in May 2013 as once-daily inhaled therapy for the treatment of chronic obstructive pulmonary disease (COPD) with umeclidinium bromide: Anoro Ellipta.

6. Pulmonary drug delivery - Wikipedia

   en.wikipedia.org/wiki/Pulmonary_drug_delivery

   Pulmonary drug delivery is mainly utilized for topical applications in the lungs, such as the use of inhaled beta-agonists, corticosteroids and anticholinergic agents for the treatment of asthma and COPD, the use of inhaled mucolytics and antibiotics for the treatment of cystic fibrosis (CT) and respiratory viral infections, [1] and the use of inhaled prostacyclin analogs for the treatment of ...

7. Aclidinium bromide - Wikipedia

   en.wikipedia.org/wiki/Aclidinium_bromide

   Aclidinium bromide is a long-acting, inhaled muscarinic antagonist (LAMA) approved in the United States in July 2012 [3] as a maintenance treatment for chronic obstructive pulmonary disease (COPD). [4] Evidence shows that it can improve quality of life and prevent hospitalization in those with COPD. [5]